share_log

Option Care Health Analyst Ratings

Option Care Health Analyst Ratings

期權護理健康分析師評級
Benzinga ·  2023/10/18 22:34
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/18/2023 33.78% JP Morgan $46 → $44 Maintains Overweight
07/28/2023 24.66% Barrington Research $34 → $41 Maintains Outperform
06/27/2023 18.58% Truist Securities → $39 Reiterates Buy → Buy
05/05/2023 3.37% Barrington Research $38 → $34 Maintains Outperform
05/05/2023 -1.19% Deutsche Bank $39 → $32.5 Maintains Buy
02/27/2023 15.54% Jefferies → $38 Reinstates → Buy
10/28/2022 15.54% Barrington Research $37 → $38 Maintains Outperform
08/22/2022 21.62% Goldman Sachs $31 → $40 Maintains Buy
07/28/2022 12.5% Barrington Research $33 → $37 Maintains Outperform
08/04/2021 -27.03% Canaccord Genuity $22 → $24 Maintains Buy
07/19/2021 -23.99% Goldman Sachs $20 → $25 Upgrades Neutral → Buy
03/12/2021 -27.03% Canaccord Genuity $20 → $24 Maintains Buy
01/22/2021 -33.11% Deutsche Bank → $22 Initiates Coverage On → Buy
01/11/2021 -36.15% JP Morgan → $21 Initiates Coverage On → Overweight
11/04/2020 -39.19% Canaccord Genuity $18 → $20 Maintains Buy
07/21/2020 -36.15% SunTrust Robinson Humphrey $18 → $21 Maintains Buy
06/24/2020 -45.27% B of A Securities → $18 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
10/18/2023 33.78% 摩根大通 $46→$44 維護 超重
07/28/2023 24.66% 巴靈頓研究公司 $34→$41 維護 跑贏大盤
2023年6月27日 18.58% Truist證券 →$39 重申 購買→購買
05/05/2023 3.37% 巴靈頓研究公司 $38→$34 維護 跑贏大盤
05/05/2023 -1.19% 德意志銀行 $39→$32.5 維護
02/27/2023 15.54% 傑富瑞 →$38 恢復 →購買
10/28/2022 15.54% 巴靈頓研究公司 $37→$38 維護 跑贏大盤
2022/08/22 21.62% 高盛 $31→$40 維護
07/28/2022 12.5% 巴靈頓研究公司 $33→$37 維護 跑贏大盤
08/04/2021 -27.03% 卡納科特·格納奇 $22→$24 維護
07/19/2021 -23.99% 高盛 $20→$25 升級 中性→購買
03/12/2021 -27.03% 卡納科特·格納奇 $20→$24 維護
2021/01/22 -33.11% 德意志銀行 →$22 開始承保 →購買
2021/11/01 -36.15% 摩根大通 →$21 開始承保 →超重
11/04/2020 -39.19% 卡納科特·格納奇 $18→$20 維護
07/21/2020 -36.15% SunTrust Robinson Humphrey $18→$21 維護
06/24/2020 -45.27% B of A證券 →$18 開始承保 →購買

What is the target price for Option Care Health (OPCH)?

OPCH的目標價格是多少?

The latest price target for Option Care Health (NASDAQ: OPCH) was reported by JP Morgan on October 18, 2023. The analyst firm set a price target for $44.00 expecting OPCH to rise to within 12 months (a possible 33.78% upside). 7 analyst firms have reported ratings in the last year.

摩根大通於2023年10月18日報道了Option Care Health(納斯達克代碼:OPCH)的最新目標價。這家分析公司將目標價定為44.00美元,預計OPCH將在12個月內上漲(可能上漲33.78%)。去年有7家分析公司公佈了評級。

What is the most recent analyst rating for Option Care Health (OPCH)?

期權護理健康(OPCH)的最新分析師評級是多少?

The latest analyst rating for Option Care Health (NASDAQ: OPCH) was provided by JP Morgan, and Option Care Health maintained their overweight rating.

Option Care Health(納斯達克股票代碼:OPCH)的最新分析師評級由摩根大通提供,Option Care Health維持其增持評級。

When is the next analyst rating going to be posted or updated for Option Care Health (OPCH)?

OPCH(OPCH)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Option Care Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Option Care Health was filed on October 18, 2023 so you should expect the next rating to be made available sometime around October 18, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與Option Care Health的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Option Care Health的上一次評級是在2023年10月18日提交的,因此您應該預計下一次評級將在2024年10月18日左右提供。

Is the Analyst Rating Option Care Health (OPCH) correct?

分析師評級選項Care Health(OPCH)正確嗎?

While ratings are subjective and will change, the latest Option Care Health (OPCH) rating was a maintained with a price target of $46.00 to $44.00. The current price Option Care Health (OPCH) is trading at is $32.89, which is out of the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的選項護理健康(OPCH)評級保持不變,目標價在46.00美元至44.00美元之間。目前的價格期權Care Health(OPCH)的交易價格為32.89美元,超出了分析師的預測區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論